FY2027 EPS Estimates for Globe Life Lowered by Analyst

Globe Life Inc. (NYSE:GL) – Investment analysts at DOWLING & PARTN lowered their FY2027 EPS estimates for shares of Globe Life in a research note issued on Monday, July 13th. DOWLING & PARTN analyst J. Hurwitz now forecasts that the company will earn $16.35 per share for the year, down from their prior forecast of $16.40. The consensus estimate for Globe Life’s current full-year earnings is $15.64 per share. DOWLING & PARTN also issued estimates for Globe Life’s FY2028 earnings at $17.95 EPS.

GL has been the topic of a number of other reports. TD Cowen lifted their target price on Globe Life from $199.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Morgan Stanley boosted their price objective on Globe Life from $181.00 to $208.00 and gave the company an “overweight” rating in a research report on Monday, July 6th. Piper Sandler upped their target price on Globe Life from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday. Jefferies Financial Group raised their target price on Globe Life from $147.00 to $166.00 and gave the stock a “hold” rating in a research report on Friday. Finally, Wells Fargo & Company lifted their price target on shares of Globe Life from $172.00 to $193.00 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $184.60.

Globe Life Stock Up 0.3%

NYSE GL opened at $179.16 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.07 and a current ratio of 0.07. The firm has a 50-day simple moving average of $164.69 and a 200 day simple moving average of $150.74. Globe Life has a twelve month low of $117.74 and a twelve month high of $182.32. The stock has a market cap of $13.91 billion, a PE ratio of 12.39 and a beta of 0.47.

Globe Life (NYSE:GL) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $3.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.46 by ($0.03). Globe Life had a return on equity of 20.94% and a net margin of 19.38%.The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the previous year, the firm posted $3.07 EPS. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Globe Life has set its FY 2026 guidance at 15.400-15.90 EPS.

Globe Life Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Monday, July 6th will be issued a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Monday, July 6th. Globe Life’s payout ratio is presently 9.13%.

Insider Buying and Selling

In other news, Director Cheryl Alston sold 8,258 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $179.24, for a total value of $1,480,163.92. Following the completion of the transaction, the director directly owned 16,621 shares of the company’s stock, valued at approximately $2,979,148.04. This represents a 33.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO James Matthew Darden sold 4,663 shares of the business’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $153.88, for a total value of $717,542.44. Following the completion of the sale, the chief executive officer directly owned 58,451 shares in the company, valued at approximately $8,994,439.88. This represents a 7.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 124,187 shares of company stock worth $19,529,414. Insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On Globe Life

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GL. Compound Planning Inc. grew its holdings in shares of Globe Life by 4.3% during the 4th quarter. Compound Planning Inc. now owns 1,968 shares of the company’s stock valued at $275,000 after purchasing an additional 82 shares during the last quarter. Root Financial Partners LLC increased its holdings in shares of Globe Life by 23.3% during the first quarter. Root Financial Partners LLC now owns 439 shares of the company’s stock worth $61,000 after buying an additional 83 shares in the last quarter. Transcend Capital Advisors LLC lifted its stake in shares of Globe Life by 3.9% in the 4th quarter. Transcend Capital Advisors LLC now owns 2,265 shares of the company’s stock valued at $317,000 after acquiring an additional 84 shares during the last quarter. Natural Investments LLC lifted its stake in shares of Globe Life by 2.6% in the 4th quarter. Natural Investments LLC now owns 3,452 shares of the company’s stock valued at $482,000 after acquiring an additional 87 shares during the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Globe Life by 5.6% during the fourth quarter. Parallel Advisors LLC now owns 1,651 shares of the company’s stock valued at $231,000 after purchasing an additional 87 shares in the last quarter. Institutional investors and hedge funds own 81.61% of the company’s stock.

About Globe Life

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.